Literature DB >> 8263163

Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro.

Z Yan1, H A Weich, W Bernart, M Breckwoldt, J Neulen.   

Abstract

Vascularization is a prerequisit for corpus luteum formation. Angiogenesis is supposed to be regulated by vascular growth factors. Vascular endothelial growth factor (VEGF) induces specifically endothelial cell proliferation as well as angiogenesis and increases capillary permeability. With this study we demonstrate for the first time the presence of VEGF-mRNA in human luteinized granulosa cells by Northern blot technique. Granulosa cells were obtained from 11 individual patients undergoing ovarian stimulation for in vitro fertilization procedure. Two transcripts of VEGF-mRNA at 3.9Kb and at 4.3Kb could be detected in each case. Specific transcripts were expressed in different amounts. These results indicate that VEGF may promote at least in part vascularization of the human corpus luteum.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8263163     DOI: 10.1210/jcem.77.6.8263163

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Angiogenesis in the corpus luteum.

Authors:  L P Reynolds; A T Grazul-Bilska; D A Redmer
Journal:  Endocrine       Date:  2000-02       Impact factor: 3.633

2.  A role for cysteine-rich 61 in the angiogenic switch during the estrous cycle in cows: regulation by prostaglandin F2alpha.

Authors:  Bo Zhang; Paul C W Tsang; Joy L Pate; Marsha A Moses
Journal:  Biol Reprod       Date:  2011-04-13       Impact factor: 4.285

3.  A rise of the serum level of von Willebrand factor occurs before clinical manifestation of the severe form of ovarian hyperstimulation syndrome.

Authors:  S Ogawa; H Minakami; S Araki; T Ohno; M Motoyama; H Shibahara; I Sato
Journal:  J Assist Reprod Genet       Date:  2001-02       Impact factor: 3.412

4.  Differential gene expression in human granulosa cells from recombinant FSH versus human menopausal gonadotropin ovarian stimulation protocols.

Authors:  John Brannian; Kathleen Eyster; Breanne A Mueller; Mandi G Bietz; Keith Hansen
Journal:  Reprod Biol Endocrinol       Date:  2010-03-12       Impact factor: 5.211

5.  Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome.

Authors:  E R Levin; G F Rosen; D L Cassidenti; B Yee; D Meldrum; A Wisot; A Pedram
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

Review 6.  VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status.

Authors:  Nikita Naredi; Pankaj Talwar; K Sandeep
Journal:  Med J Armed Forces India       Date:  2012-09-11

7.  [Correlation between follicular fluid sRAGE level and ovarian responsiveness in non-PCOS patients undergoing controlled ovarian hyperstimulation].

Authors:  Meiling Li; Yong Shao; Haiyan Fu; Cheng Zhou; Bing Yao; Yong Tan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-12-30

8.  Ovarian VEGF(165)b expression regulates follicular development, corpus luteum function and fertility.

Authors:  Y Qiu; M Seager; A Osman; J Castle-Miller; H Bevan; D J Tortonese; D Murphy; S J Harper; H M Fraser; L F Donaldson; D O Bates
Journal:  Reproduction       Date:  2012-01-09       Impact factor: 3.906

9.  Regulation of soluble vascular endothelial growth factor receptor (sFlt-1/sVEGFR-1) expression and release in endothelial cells by human follicular fluid and granulosa cells.

Authors:  Ruth Gruemmer; Karin Motejlek; Daniela Berghaus; Herbert A Weich; Joseph Neulen
Journal:  Reprod Biol Endocrinol       Date:  2005-10-25       Impact factor: 5.211

Review 10.  Volume expanders for the prevention of ovarian hyperstimulation syndrome.

Authors:  Mohamed A Youssef; Selma Mourad
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.